Aminoethylation process for production of substituted ethylene diamines |
| What is claimed is: 1. A process for preparing a 1,2-ethanediamine in a ring opening reaction of an ... |
|
Transdermal thermal polymerization |
| The present invention, in one aspect, is a method for polymerizing or crosslinking by transdermal ... |
|
Method for identifying an oligonucleotide aptamer specific for a target |
| We claim: 1. A method for identifying an aptamer which specifically binds to thrombin, wherein the ... |
|
Plant transcription regulators from circovirus |
| OF THE INVENTION The present invention is further described by reference to the following non-... |
|
Methods for modulation of the effects of aging on the primate brain |
| The invention provides a clinically useful protocol for delivery of recombinant nervous system ... |
|
Genetic engineering of cells to enhance healing and tissue regeneration |
| OF THE INVENTION It has been discovered that cells can be genetically engineered to produce ... |
|
Vascular endothelial growth factor-D (VEGF-D) polypeptides |
| OF THE INVENTION The invention will now be described in detail by reference to the figures, and to ... |
|
Methods for treating viral infection using IL-28 and IL-29 |
| We claim: 1. A method of treating a viral infection comprising administering to an ... |
|
Method of manufacturing an electrohydraulic probe |
| OF THE INVENTION Referring to FIG. 1 there is shown a diagrammatical view of the bladder 2, ureter ... |
|
Releasable linkage and compositions containing same |
| Accordingly, it is an object of the invention to provide a compound where a ligand is covalently ... |
|
|
Method and apparatus for administration of anticoagulant to red cell suspension output of a blood separator
| Details |
Inventors: Schoendorfer, Donald W.;
Assignee: Baxter International Inc. (Deerfield, IL)
Primary Examiner: Jones; W. Gary
Assistant Examiner:
Attorney, Agent or Firm: Price; Bradford R. L., Ryan; Daniel D., Flattery; Paul C.
Method and apparatus for machine separation of blood and blood components that utilizes improved administeration of anticoagulant to the red cell suspension output. Anticoagulant is added to incoming whole blood in an amount sufficient to prevent clotting of the whole blood in the flow path upstream of the blood component separator, but in an amount insufficient to prevent clotting of the red cell suspension created by the separator. Anticoagulant is added to the red cell suspension downstream of the separator in order to prevent clotting. By adding an additional aliquot of anticoagulant to the red cell suspension, the amount of anticoagulant added to whole blood before separation can be reduced or eliminated, resulting in an increase in platelet yield during the blood component separation step. |
|
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Referring now to the drawings, particularly to FIG. 1, there is illustrated a separation set, generally designated 10, such as described in aforementioned U. S. Pat. No. 4,851,126. The set 10 includes tubing 11 and separators 46, 62 defining flow path means. The set 10 may be applied to a microprocessor controlled hemapheresis instrument, such as the instrument H illustrated in FIGS. 2 and 3, in a manner to effect collection of whole blood from a donor through a single needle; separation of the whole blood into packed blood cells and platelet-rich plasma (PRP); reinfusion of the packed blood cells to the donor, (or alternatively, transfer of some of the packed red cells to a red blood cell collection container); and subsequent separation of platelets from the platelet-rich plasma to provide platelet concentrate and cell depleted, platelet-poor plasma (PPP). While in the preferred embodiments the set 10 is described in conjunction with a single needle with its attendant features and advantages, it will be appreciated that the invention is also applicable to two-needle systems. Set 10 is provided with a single phlebotomy needle 12 for alternately receiving whole blood from a donor and reinfusing one or more blood fractions such as packed red cells back into the donor. The needle 12 communicates with a blood line 14. An anticoagulant line 16 has an anticoagulant spike 18 at one end for reception in an anticoagulant supply container 20, illustrated in FIG. 2. At the opposite end, anticoagulant line 16 joins blood line 14 in a Y-connection 13 closely adjacent the single phlebotomy needle 12. The set 10 also includes a reservoir 22. The reservoir 22 is divided into a pair of side-by-side compartments 24, 26. Ports 28 and 30 are provided at the lower ends of the compartments 24, 26, respectively. Mesh screen/filter tubes 32, 34 are disposed in compartments 24, 26, respectively, in communication with respective inlet ports 36 and 38 at the upper end of the reservoir 22
|
| Related patents |
|
|
Electroporation device
I claim: 1. An electroporation apparatus for electroporating living cells with molecules comprising: (a) first and second electrodes, respectively having, first and ...
|
|
|
Implantable electroporation method and apparatus for drug and gene delivery
Accordingly, it is the primary object of the present invention to provide an improved method of electroporation mediated, in vivo, intracellular drug and gene delivery ...
|
|
|
Flow electroporation chamber with electrodes having a crystalline metal nitride coating
The present invention provides improved electrodes for use in generating an electrical field in a saline solution. In particular, the invention relates to continuous ...
|
|
|
Solely pollen-specific promoter
What is claimed is: 1. An isolated solely pollen-specific promoter derived from Arabidopsis comprising a complete nucleotide sequence of SEQ ID NO: 1 derived from the A...
|
|
|
Gene transfer using transformed, neodetermined, embryonic cells
This invention relates to the preparation of carrier cells capable of delivering genetic material to a particular tissue of the body by means of embryonic cells ...
|
|
|
Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
The present invention provides methods and compositions for inhibiting loss of bone mass, and/or for stimulating bone formation in mammals, particularly humans. In one ...
|
|
|
Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
The present invention provides for cationic amphiphiles that are particularly effective to facilitate transport of biologically active molecules into cells. R...
|
|
|
Cationic amphiphiles containing multiplesteroid lipophilic groups
The present invention provides for cationic amphiphiles that are particularly effective to facilitate transport of biologically active molecules into cells. R...
|
|
|
N-terminally chemically modified protein compositions and methods
What is claimed is: 1. A preparation comprising a predominant amount of a monopolymer/protein conjugate prepared from a hematopoietic protein having one or more ...
|
|
|
Membrane virus host range mutations and their uses as vaccine substrates
What is claimed is: 1. A genetically engineered Arbovirus comprising, a transmembrane glycoprotein with a deletion of one or more amino acids in a transmembrane domain ...
|
|
|